Brasília, Brazil
Brasília, Brazil

Time filter

Source Type

Strekin AG, a privately held clinical-stage biopharmaceutical company, announced today the presentation of new preclinical data and an update on Strekin's Phase 2 clinical development program for STR001 in the treatment of hearing loss at the Association for Research in Otolaryngology Conference (ARO), Baltimore, USA. STR001-201 is a Phase 2 clinical trial of STR001 intratympanic injection for the treatment of Sudden Sensorineural Hearing Loss (SSHL) caused by Cochlear Implantation (CI) surgery. An undesired outcome of CI is the loss of residual low-frequency hearing due to electrode insertion. STR001-201 is an international, multicenter, randomized, placebo-controlled trial evaluating the efficacy, safety and tolerability of STR001-IT in 110 patients undergoing CI.  As of 10 Feb 2017, the STR001-201 trial has enrolled 50 patients in four countries.  STR001-IT treatment has been very well tolerated with no adverse events of concern identified. Top-line clinical trial results are expected in the 4th quarter of 2017. In a poster presentation (#PS792) entitled "Peroxisome proliferator activated receptor -gamma and -alpha agonists protect auditory hair cells from gentamicin-induced oxidative stress and apoptosis", researchers observed that the PPAR agonist pioglitazone, the active ingredient in STR001, was highly effective in preventing damage to sensory hair cells of the inner ear. The research was led by Daniel Bodmer, MD, PhD, and Chairman of the Department of Otolaryngology Head & Neck Surgery at the University Hospital of Basel, Switzerland. Dr. Bodmer's analysis was performed in a model in hearing research in which the organ of Corti, the structure containing auditory hair and sensory cells, was studied in tissue culture. Treatment of cultures with gentamicin, an antibiotic that leads to hearing loss in humans, caused loss of hair cells which was almost completely prevented by STR001.  Further analysis showed that gentamicin induced oxygen free radicals, promoted lipid oxidation, and activated the cell death pathway (apoptosis) in hair cells, all of which were prevented by STR001. In a second presentation (PS159) entitled "Intra-tympanic Administration of Pioglitazone, a Peroxisome Proliferator-Activated Receptor Gamma Agonist, Protects from Noise-Induced Hearing Loss"  Dr. Anna-Rita Fetoni and her colleagues from the Catholic University of Rome, showed that a single intratympanic injection of STR001-IT was highly effective in a rodent model of noise-induced hearing loss. STR001 promted complete recovery of hearing when given shortly afer noise. Recovery was accompanied by a strong reduction in markers of oxidative stress in auditory hair cells. Delayed STR001 treatment to 48h after noise promoted partial recovery, which has not, to our knowledge, been shown for other drugs. These data, together with the data from Dr. Bodmer's group, suggest that STR001 has the potential to be a new and differentiated therapy for many types of hearing loss through favorable effects on multiple pathways. Strekin is a privately held clinical-stage biopharmaceutical company in Basel, Switzerland. Strekin is led by an experienced team in research and clinical development. Strekin has secured funding to complete the Phase 2 study of STR001 and to pursue further development with the support of investors and partners. According to the World Health Organization, 642 million people around the world including 181 million children suffer from disabling hearing loss. Daily activities that most people take for granted, like having a conversation, enjoying music, and advancing in the workplace, are difficult or impossible for individuals suffering from hearing loss. With no approved pharmaceutical therapies available today, there is urgency to develop effective treatments.


News Article | February 15, 2017
Site: www.prweb.com

Edward Buckingham MD, founder of the Buckingham Center for Facial Plastic Surgery, was recently in attendance at the elite International Facial Plastic Surgery Winter Symposium – Reaching New Peaks in Facial Plastic Surgery. Held annually, this retreat hosts the top facial plastic surgeons, oculoplastic surgeons, dermatologists and aesthetic professionals from around the world. Dr. Buckingham had the pleasure of acting as course director for the 2017 event, along with Rami K. Batniji, MD.   The Winter Facial Plastic Surgery International meeting was held at Beaver Creek Mountain, outside of Vail, from January 18-22, 2017. This biannual meeting is well-known for offering an intimate level of interaction between presenters and attending physicians. This year, the prestigious faculty included more than 40 renowned surgeons.   The five-day conference served as the hub for a variety of educational presentations, lectures, classes and exhibitions. Presentation topics included ‘Revision Rhinoplasty – How to Avoid It’, ‘Fat Transfer with Rhytidectomy’, ‘Treating the Advanced Aging of the Lower Third of the Neck’, ‘A Minimally Invasive Approach to Lower Eyelid Retraction’ and ‘Periocular Fillers’, as well as many others. Each day began with an exhibitor breakfast, ending with specialty-specific lectures, discussions and après-ski. All of those in attendance received 20 continuing education credits.   Dr. Buckingham is an alumnus of Southern Methodist University and the University of Texas, Double Board Certified by the American Board of Facial Plastic and Reconstructive Surgery and the American Board of Otolaryngology. The Austin-area native graduated in the top 2% of his medical school class at the University of Texas Medical Branch in Galveston. During this time, Dr. Buckingham was awarded the ‘prestigious’ Donald Duncan Memorial Scholarship in Anatomy, the Merck Manual Award and the Edward Randall Medal for Academic Excellence. A leader in the field of facial plastic surgery, Dr. Buckingham is one of a small group of doctors to achieve the highest possible written score on the American Board of Facial Plastic and Reconstructive Surgery’s certification examination.   To get additional details on Buckingham Center for Facial and Plastic Surgery, contact the Austin office at 512.401.2500. Personal consultations with Dr. Buckingham can be arranged in-person, as well as via email. Information on the recent International Facial Plastic Surgery conference, and all this year’s speakers, can be found at the Winter Symposium’s online program.


News Article | February 15, 2017
Site: www.prweb.com

Edward Buckingham MD, founder of the Buckingham Center for Facial Plastic Surgery, is excited to announce that he has been nominated as one of America’s Best Physicians for 2017. This is the third year in a row that he has been recognized by the National Consumer Advisory Board for providing top-notch cosmetic surgery care. In 2015 and 2016, Dr. Buckingham was awarded the designation of America’s Best Physician, as well. The National Consumer Advisory Board (NCAB) is a one-of-a-kind, privately run, organization dedicated to ensuring potential patients can find the safest medical care available. Only doctors with outstanding credentials and a superior record of patient care can be considered for the title of America’s Best Physician. To be included, these physicians are required to demonstrate a high level of professionalism within their specialty, meeting rigorous continuing education and annual training requirements. As part of the NCAB’s impartial methodology of choosing providers for their America’s Best Physicians’ directory, doctors are first nominated by their peers and colleagues. Doctors are then selected to receive the title if they have met specific career benchmarks, which includes holding more than four years of clinical experience and exceeding the required level of continuing education, as well as demonstrating a marked online presence through exceptional patient reviews. Dr. Buckingham is proud to be nominated for the NCAB’s prestigious title of America’s Best Physician for the third year in a row. “Here at the Buckingham Center for Facial Plastic Surgery, we specialize only in cosmetic and reconstructive surgery of the face and neck. In fact, all of my training has been in surgery of the face and neck.” He continues, “I am beyond honored to be recognized (for this award) by my esteemed peers.” Double Board Certified by the American Board of Facial Plastic and Reconstructive Surgery and the American Board of Otolaryngology, Dr. Buckingham is an Austin-area native. He received his BBA from Southern Methodist University, attended the University of Texas at Austin and received his medical degree from the University of Texas Medical Branch in Galveston, where he graduated in the top 2% of his class. For his hard work, Dr. Buckingham was awarded the ‘prestigious’ Donald Duncan Memorial Scholarship in Anatomy, the Merck Manual Award and the Edward Randall Medal for Academic Excellence. Dr. Buckingham is one of a small group of physicians to have achieved the highest written score on the certification examination given by the American Board of Facial Plastic and Reconstructive Surgery. To get more information on the Buckingham Center for Facial Plastic Surgery, contact the Austin office at 512.401.2500. Consultations with Dr. Buckingham can be scheduled in-person or requested online; speak with a patient coordinator to find out more. Additional details on the title of America’s Best Physician can be found on the award’s website or from the National Consumer Advisory Board.


News Article | February 15, 2017
Site: www.prnewswire.co.uk

Strekin AG, una compañía biofarmacéutica de propiedad privada y en fase clínica, anunció hoy la presentación de los nuevos datos preclínicos y la actualización del programa de desarrollo clínico en fase 2 de Strekin para STR001 en el tratamiento de la pérdida auditiva durante la celebración de la Association for Research in Otolaryngology Conference (ARO) en Baltimore, Estados Unidos. STR001-201 es un ensayo clínico en fase 2 de la inyección intra-timpánica STR001 para el tratamiento de la pérdida auditiva repentina sensorineural (SSHL) causada por la cirugía de implantación coclear (CI). Un resultado no deseado de CI es la pérdida de audición residual de baja frecuencia debido a la inserción de electrodos. STR001-201 es un ensayo internacional, multicentro, aleatorio y controlado por placebo que evaluó la eficacia, seguridad y tolerabilidad de STR001-IT en 110 pacientes con CI. A fecha de 10 de febrero de 2017, el ensayo STR001-201 había reclutado a 50 pacientes en cuatro países. El tratamiento con STR001-IT se había tolerado correctamente y sin efectos secundarios preocupantes identificados. Los resultados de los ensayos clínicos de primera línea se esperan para el cuarto trimestre de 2017. En una presentación poster (#PS792) titulada "Peroxisome proliferator activated receptor -gamma and -alpha agonists protect auditory hair cells from gentamicin-induced oxidative stress and apoptosis", los investigadores han observado que la pioglitazona agonista PPAR, ingrediente activo de STR001, fue altamente eficaz en la prevención de los daños de las células sensoriales del pelo del interior de la oreja. La investigación la dirigió Daniel Bodmer, doctor, PhD y presidente del Department of Otolaryngology Head & Neck Surgery del Hospital Universitario de Basilea, Suiza. El análisis del doctor Bodmer lo llevó a cabo en un modelo de investigación de audición en el que el órgano de Corti, la estructura que contiene el pelo auditorio y células sensoriales, se estudió dentro del cultivo del tejido. El tratamiento de los cultivos con gentamicina, un antibiótico que lleva a la pérdida de audición en los humanos, causó una pérdida de células de pelo que era casi completamente prevenible con STR001. Un análisis posterior demostró que los radicales sin oxígeno inducidos por gentamicina promueven la oxidación de los lípidos y activan la ruta de muerte celular (apoptosis) en las células de los pelos, todo ello prevenible con STR001. En una segunda presentación (PS159) titulada "Intra-tympanic Administration of Pioglitazone, a Peroxisome Proliferator-Activated Receptor Gamma Agonist, Protects from Noise-Induced Hearing Loss", la doctora Anna-Rita Fetoni y sus colegas de la Universidad Católica de Roma, demostraron que una única inyección intra-timpánica de STR001-IT fue altamente eficaz en un modelo de roedor con pérdida de audición inducida por ruido. STR001 promovió la recuperación completa de audición cuando se le suministró justo después del ruido. La recuperación estuvo acompañada de una reducción destacada en los marcadores de estrés de oxidación en las células de pelos de audición. El tratamiento retrasado con STR001 hasta 48 horas después del ruido promocionó una recuperación parcial, que por lo que sabemos, no se ha demostrado en otros fármacos. Estos datos, junto a los datos del grupo del doctor Bodmer, sugieren que STR001 cuenta con potencial para ser una terapia nueva y diferente de muchos tipos de pérdida auditiva a través de los efectos favorables en múltiples rutas. Strekin es una compañía de ciencias de la vida en fase clínica de propiedad privada localizada en Basilea, Suiza. Strekin está dirigida por un equipo experimentado con un fuerte historial en investigación y desarrollo clínico. Strekin está financiada suficientemente para completar el estudio de fase 2 de STR001 y preparar otros desarrollos clínicos con el apoyo de inversores o socios. Según la Organización Mundial de la Salud, 642 millones de personas de todo el mundo, incluyendo 181 millones de niños, sufren hoy de pérdida auditiva discapacitadora. Las actividades diarias que la mayoría de las personas dan por hecho, como tener una conversación, escuchar música y avanzar en el espacio de trabajo, son difíciles o imposibles para las personas que padecen pérdida auditiva. Sin terapias farmacéuticas aprobadas disponibles hoy, hay una renovada urgencia por desarrollar tratamientos efectivos para la pérdida auditiva.


Strekin AG, ein auf klinischer Stufe aktives Biopharma-Unternehmen im Privatbesitz, gab heute bei der Konferenz der Association for Research in Otolaryngology (ARO) in Baltimore, USA, neue Daten bekannt. Strekin präsentierte neue präklinische Daten und ein Update ihres klinischen Phase-2-Programms: STR001 zur Behandlung von Hörverlust. STR001-201 ist eine klinische Phase-2-Studie mit intratympanisch injiziertem STR001 zur Behandlung von Hörstürzen (Sudden Sensorineural Hearing Loss, SSHL) verursacht durch eine Cochlea-Implantation (CI). Eine unerwünschte Nebenwirkung einer CI ist der Verlust des Restgehörs im Niedrigfrequenzbereich aufgrund des Einführens der Elektrode. STR001-201 ist eine internationale randomisierte, Placebo-kontrollierte multizentrische Studie, welche die Wirksamkeit, Sicherheit und Verträglichkeit von STR001-IT bei 110 Patienten untersucht, die eine CI durchlaufen.  Nach Stand vom 10. Februar 2017 wurden bei der STR001-201-Studie 50 Patienten in vier Ländern eingeschlossen.  Die Behandlung mit STR001-IT wurde sehr gut vertragen und es traten keine unerwünschten Ereignisse auf. Topline-Ergebnisse der klinischen Tests werden voraussichtlich im 4. Quartal 2017 zur Verfügung stehen. In einer Poster-Präsentation (#PS792) mit dem Titel "Peroxisome proliferator activated receptor -gamma and -alpha agonists protect auditory hair cells from gentamicin-induced oxidative stress and apoptosis" [Peroxisom-Proliferator-aktivierte Rezeptor-Gamma- und Alpha-Agonisten schützen Hörhaarzellen vor Gentamicin-induziertem oxidativem Stress und Apoptose] stellten die Forscher fest, dass der PPAR-Agonist Pioglitazon (der Wirkstoff von STR001) höchst effektiv zur Vermeidung von Schäden an den Sinneshaarzellen im Innenohr beitrug. Die Forschungsarbeiten wurden geleitet von Professor Dr. Daniel Bodmer, MD, PhD und Chefarzt, Leiter Otolaryngologie, Schädelbasis, Leiter Zentrum für Kopf-, Hals- und Augentumore am Universitätsspital von Basel, Schweiz. Prof. Dr. Bodmers Analyse wurde an einem Modell der Gehörforschung durchgeführt, in dem das Corti'sche Organ, welches die Hörhaare und Sinneszellen enthält, innerhalb einer Gewebekultur untersucht wurde. Die Behandlung der Kulturen mit Gentamicin, einem Antibiotikum, das bei Menschen einen Hörverlust hervorruft, führte zum Verlust der Haarzellen, welcher durch STR001 beinahe vollständig vermieden werden konnte.  Weitere Analysen ergaben, dass Gentamicin freie Sauerstoffradikale induzierte, eine Lipid-Oxidation förderte und den Zelltod-Signalweg (Apoptose) aktivierte, was alles durch STR001 verhindert wurde. In einer zweiten Präsentation (PS159) mit dem Titel "Intra-tympanic Administration of Pioglitazone, a Peroxisome Proliferator-Activated Receptor Gamma Agonist, Protects from Noise-Induced Hearing Loss" [Intratympanische Verabreichung von Pioglitazon, einem Proliferator-aktivierten Rezeptor-Gamma-Agonisten, schützt vor lärmbedingtem Hörverlust]  zeigten Dr. Anna-Rita Fetoni und ihre Kolleginnen und Kollegen von der Katholischen Universität Rom, dass eine einzige intratympanische Injektion von STR001-IT an einem Nagetier-Modell mit lärmbedingtem Hörverlust sehr effektiv war. Bei einer Verabreichung kurz nach Auftreten des Lärms erzielte STR001 eine vollständige Genesung des Gehörs. Die Genesung ging mit einer starken Verminderung an Markern von oxidativem Stress in den Hörhaarzellen einher. Eine verzögerte Behandlung mit STR001 bis zu 48 Stunden nach Auftreten des Lärms führte zu einer teilweisen Genesung, was sich unserem Kenntnisstand nach bei anderen Medikamenten bislang nicht nachweisen ließ. Diese Daten, in Verbindung mit denen von Prof. Dr. Bodmers Gruppe, lassen vermuten, dass STR001 das Potenzial hat, zu einer neuen und differenzierte Therapie für verschiedene Arten von Hörverlust zu werden, da es positive Auswirkungen auf mehrere Signalwege hat. Strekin ist ein auf klinischer Stufe aktives Biopharma-Unternehmen im Privatbesitz mit Sitz in Basel, Schweiz. Strekin wird von einem erfahrenen Team aus Forschung und klinischer Entwicklung geleitet. Strekin konnte ausreichend Finanzmittel beschaffen, um die Phase-2-Studie von STR001 abzuschließen und die weitergehende klinische Entwicklung mit Unterstützung von Investoren oder Partnern fortzusetzen. Nach Angaben der Weltgesundheitsorganisation leiden heutzutage weltweit 642 Millionen Menschen an Hörverlust, darunter 181 Millionen Kinder, der mit erheblichen Beeinträchtigungen einhergeht,. Alltägliche Aktivitäten, die für die Meisten selbstverständlich sind − wie Gespräche führen, Musik hören und sich beruflich weiterentwickeln − sind schwierig oder gar unmöglich für Menschen, die unter Hörverlust leiden. Da bis heute keine zugelassenen pharmazeutischen Therapien verfügbar sind, ist es dringend erforderlich, effektive Therapien zur Behandlung von Hörverlust zu entwickeln.


News Article | February 18, 2017
Site: www.eurekalert.org

Patients who complain they can't hear their friends at a noisy restaurant, but pass a hearing test in their doctor's office, may be describing hidden hearing loss. Now, less than six years since its initial description, scientists have made great strides in understanding what hidden hearing loss is and what causes it. In research published in Nature Communications, University of Michigan researchers report a new unexpected cause for this auditory neuropathy, a step toward the eventual work to identify treatments. "If people can have hidden hearing loss for different reasons, having the ability to make the right diagnosis of the pathogenesis will be critical," says author Gabriel Corfas, Ph.D., director of the Kresge Hearing Research Institute at Michigan Medicine's Department of Otolaryngology - Head and Neck Surgery. Corfas published the research with co-author Guoqiang Wan, now with Nanjing University in China. They discovered using mice that disruption in the Schwann cells that make myelin, which insulates the neuronal axons in the ear, leads to hidden hearing loss. This means hidden hearing loss could be behind auditory deficits seen in acute demyelinating disorders such as Guillain-Barré syndrome, which can be caused by Zika virus. Corfas and Wan used genetic tools to induce loss of myelin in the auditory nerve of mice, modeling Guillain-Barré. Although the myelin regenerated in a few weeks, the mice developed a permanent hidden hearing loss. Even after the myelin regenerated, damage to a nerve structure called the heminode remained. When the ear is exposed to loud noises over time, synapses connecting hair cells with the neurons in the inner ear are lost. This loss of synapses has previously been shown as a mechanism leading to hidden hearing loss. In an audiologist's quiet testing room, only a few synapses are needed to pick up sounds. But in a noisy environment, the ear must activate specific synapses. If they aren't all there, it's difficult for people to make sense of the noise or words around them. That is hidden hearing loss, Corfas says. "Exposure to noise is increasing in our society, and children are exposing themselves to high levels of noise very early in life," Corfas says. "It's clear that being exposed to high levels of sound might contribute to increases in hidden hearing loss." The newly identified cause -- deficiency in Schwann cells -- could occur in individuals who have already had noise exposure-driven hidden hearing loss as well. "Both forms of hidden hearing loss, noise exposure and loss of myelin, can occur in the same individual for an additive effect," Corfas says. Previously, Corfas' group succeeded in regenerating synapses in mice with hidden hearing loss, providing a path to explore for potential treatment. While continuing this work, Corfas started to investigate other cells in the ear, which led to uncovering the new mechanism. There are no current treatments for hidden hearing loss. But as understanding of the condition improves, the goal is for the research to lead to the development of drugs to treat it. "Our findings should influence the way hidden hearing loss is diagnosed and drive the future of clinical trials searching for a treatment," Corfas says. "The first step is to know whether a person's hidden hearing loss is due to synapse loss or myelin/heminode damage."


News Article | February 22, 2017
Site: www.rdmag.com

The loss of tiny, sound-sensing cells in the inner ear, known as "hair cells," is a leading cause of hearing loss, a public health problem affecting at least 5 percent of the world population. Hair cells, which do not regenerate on their own, can die away from a variety of factors including excessive noise exposure, certain medications, infection and as part of the natural aging process. In 2013, Massachusetts Eye and Ear researchers successfully regenerated hair cells and restored partial hearing to mice by converting cells found in the inner ear into hair cells. However, the success of restoring hearing through this approach was limited by the small number of cells that could be turned into hair cells. In a study published online today in Cell Reports, a research team from Mass. Eye and Ear, Brigham and Women's Hospital and Massachusetts Institute of Technology has shown that LGR5+ cells can be augmented to a much higher volume and then converted into hair cells, lending hope that full hearing can be restored to those with hearing loss due to damaged hair cells. From a single mouse, the team generated more than 11,500 hair cells (compared to less than 200 hair cells generated without efforts to augment). "We have shown that we can expand Lgr5-expressing cells to differentiate into hair cells in high yield, which opens the door for drug discovery for hearing," said senior author Albert Edge, Ph.D., Director of the Tillotson Cell Biology Unit at Mass. Eye and Ear and a Professor of Otolaryngology at Harvard Medical School. "We hope that by stimulating these cells to divide and differentiate that we will improve on our previous results in restoring hearing." The researchers were encouraged by a previous Mass. Eye and Ear discovery that the inner ear contained stem cells that could be turned into hair cells in a dish. These cells contained a protein called Lgr5, which is found in adult intestinal stem cells, where they actively regenerate to replace the entire lining of human intestines every 8 days. Their regenerative properties motivated the researchers to explore their potential use in hair cell regeneration in the ear, and they were able to turn the Lgr5+ cells into new hair cells in the live animal in response to a series of signals known as the Wnt pathway, which could be stimulated by a drug treatment. In the experiments described in Cell Reports, the researchers extracted the Lgr5+ cells from the inner ears of mice, placed them in a dish and used a combination of drugs and growth factors to make them multiply. They then treated the cells with a second drug cocktail to convert the expanded Lgr5+ cells into large populations of hair cells. Their results identify drugs that will be useful for a combination of first expanding Lgr5+ cells in the inner ear and then converting them to hair cells, opening the door for better therapies to be developed to restore hearing to those with acquired forms of deafness. "With this knowledge, we can make better shots on goal, which is critical for repairing damaged ears," said Dr. Edge. "We have identified the cells of interest and have identified the pathways and drugs to target to improve on previous results. These clues may lead us closer to finding drugs that could treat hearing loss in adults."


Dr. Patrick Sullivan will be speaking and moderating panel discussions on fat injections, stem cell treatment controversies, facial rejuvenation, blepharoplasty and more at the 2017 ASPS Aesthetica Super Symposium in New Orleans, LA PROVIDENCE, RI--(Marketwired - Mar 2, 2017) -  Board-certified Rhode Island plastic surgeon Patrick Sullivan, MD has been invited to speak and lead panels at the upcoming Aesthetica Super Symposium. Sponsored by the American Society of Plastic Surgeons (ASPS), the conference will take place in New Orleans, LA from March 2-4, 2017. Dr. Sullivan says he is honored to have been invited as a member of this esteemed faculty and to speak on a number of topics at the upcoming Aesthetica meeting in New Orleans. "It is always an honor to be asked to present your special treatments and experience to plastic surgeons from the United States and around the world," he notes. "It is also a special opportunity to discuss the importance of artistic planning of the procedure and its correlation to achieving more natural results." The topics on which Dr. Sullivan will be speaking and moderating span from special face lift techniques, neck lift and fat grafting to eyelid surgery and new plastic surgery technologies. Although the titles and specific techniques addressed throughout each of his presentations will change, the larger message delivered will be consistent: how to achieve the ultimate goal of lasting, consistent and natural results. Dr. Sullivan's approach to plastic surgery and the key to achieving natural results starts with artistic planning. Ultimately, he believes this message will benefit the plastic surgery field as a whole. If plastic surgeons are able to provide natural results more consistently, patients will achieve their ultimate goals, and the treatments will improve throughout the field. This year's Aesthetica Super Symposium will be held at the New Orleans Marriott from March 2nd through March 4th and will feature over 40 exhibits and presentations from plastic surgeons throughout the country. There is an exciting section of the meeting titled Ideas and Innovations (I3) -- where Dr. Sullivan will share tips and principles that can improve results. About the American Society of Plastic Surgeons Founded in 1931, ASPS is the largest plastic surgery specialty organization in the world. Its website is also one of the most frequented for those looking for more information on specific procedures and locating the most qualified plastic surgeon. Their mission focuses on safety and quality of care for patients. ASPS provides support and education for its members while also holding them to the highest professional and ethical standards. To learn more, visit www.plasticsurgery.org. About Patrick Sullivan, MD Dr. Sullivan is Division Chief of Cosmetic Surgery at Brown University's School of Medicine in Providence, and he has been recognized as being in the top 1% of plastic surgeons in America by US News & World Report. Certified by the American Board of Plastic Surgery and the American Board of Otolaryngology, he is a highly skilled and experienced plastic surgeon who offers a wide range of aesthetic treatments for the face, body and breasts. Dr. Sullivan is available for interview upon request. To view the original source of this press release, click here: http://www.drsullivan.com/news-media/rhode-island-plastic-surgeon-to-share-new-treatments-at-asps-aesthetica-super-symposium-2017/


BASEL, Schweiz, February 15, 2017 /PRNewswire/ -- Strekin AG, ein auf klinischer Stufe aktives Biopharma-Unternehmen im Privatbesitz, gab heute bei der Konferenz der Association for Research in Otolaryngology (ARO) in Baltimore, USA, neue Daten bekannt. Strekin präsentierte neue...


Strekin AG, entreprise bio-pharmaceutique privée en phase cliniques, a annoncé aujourd'hui la présentation de nouvelles données à l'occasion de la conférence de l'Association for Research in Otolaryngology (ARO), à Baltimore, aux États-Unis. Strekin a présenté des nouvelles données pré-cliniques et les pus récentes avancées de la phase 2 de son programme de développement du STR001 pour le traitement de la perte auditive. STR001-201 est la phase 2 de l'essai clinique du traitement par injection trans-tympanique STR001 contre la surdité subite de perception (SSP) causée par la pose d'un implant cochléaire (IC). L'un des effets indésirables possibles suite à la pose d'un IC est la perte des basses fréquences résiduelles pouvant être causée par l'insertion de l'électrode. STR001-201 est un essai international, multi-centrique, randomisé et sous contrôle placebo, qui a pour objectif l'évaluation de l'efficacité, de l'innocuité et de la tolérabilité du STR001-IT chez 110 patients devant recevoir un IC.  Depuis le 10 février 2017, l'essai STR001-201 regroupe 50 patients issus de quatre pays.  Le traitement par STR001-IT est bien toléré et n'a causé aucun effet indésirable identifié. Les résultats définitifs de l'essai clinique sont attendus pour le 4e trimestre 2017. Lors d'une séance d'affichage et de démonstration (#PS792) intitulée « Les PPAR agonistes gamma et alpha protègent les cellules capillaires auditives contre les effets oxydants de la gentamicine et l'apoptose », des chercheurs ont observé que le PPAR agoniste pioglitazone, l'élément actif du STR001, était très efficace pour protéger les cellules capillaires auditives de l'oreille interne. Cette étude était dirigée par Daniel Bodmer, MD, PhD, et directeur du département d'otorhinolaryngologie et de chirurgie de la tête et du cou à l'hôpital universitaire de Bâle, en Suisse. L'analyse du Dr Bodmer a été menée à partir d'un modèle en recherche auditive, pour lequel l'organe de Corti, structure contenant les cellule capillaire auditives, a été étudié sous forme de culture cellulaire. L'exposition des cultures à la gentamicine, un antibiotique qui peut causer la perte auditive chez l'homme et la destruction de cellules capillaires auditives, a pu être complétement évitée grâce au STR001.  Une analyse plus poussée a permis de montrer que la gentamicine provoquait l'apparition de radicaux libres dans l'oxygène et une oxydation des lipides activant la dégénérescence des cellules capillaires (apoptose), autant de réactions que le STR001 a permis d'éviter. Lors d'une seconde présentation (PS159) intitulée « L'administration trans-tympanique de pioglitazone, un PPAR agoniste gamma, prévient la perte auditive liée au bruit », le Dr Anna-Rita Fetoni et ses collègues de l'université catholique de Rome ont démontré l'efficacité d'une injection trans-tympanique unique de STR001-IT sur un cobaye exposé à une perte auditive liée au bruit.  Le STR001 a permis un rétablissement complet des lésions liées au bruit lorsqu'il était administré peu de temps après le traumatisme. Le rétablissement était accompagné d'une baisse considérable des marqueurs de stress oxydant des cellules capillaires auditives. Le traitement au STR001 administré 48 heures après le traumatisme permettait d'accéder à un rétablissement partiel, ce qui n'a pas pu être démontré, autant que nous le sachions, pour aucun autre traitement. Ces données, ainsi que celles recueillies par le groupe du Dr Bodmer, suggèrent que le STR001 a le potentiel de devenir une nouvelle thérapie distinctive pour de nombreux types de perte auditive grâce à ses effets positifs sur les voies métaboliques. Située à Bâle (Suisse), Strekin est une entreprise bio-pharmaceutique privée en phase clinique. Strekin est dirigée par une équipe d'experts en recherche scientifique et en développement clinique. Strekin a réuni les fonds nécessaires à la réalisation de la phase 2 de l'étude portant sur le STR001 et à la poursuite de nouveaux développements grâce au soutien d'investisseurs et de ses partenaires. Selon l'Organisation mondiale de la santé, 642 millions de personnes dans le monde, dont près de 181 millions d'enfants, souffrent d'une perte auditive handicapante. Un grand nombre d'activités quotidiennes, banales pour la plupart des gens, telles que prendre part à une conversation, écouter de la musique ou évoluer dans un environnement professionnel, sont difficiles voire impossibles pour les individus souffrant de perte auditive. En l'absence de traitements pharmaceutiques approuvés, il est urgent de développer des traitements efficaces contre la perte auditive.

Loading Otolaryngology collaborators
Loading Otolaryngology collaborators